- Home
- ZVRA vs AUTL Comparison
ZVRA vs AUTL Comparison
Compare ZVRA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- AUTL
- Stock Information
- Founded
- ZVRA 2006
- AUTL 2014
- Country
- ZVRA United States
- AUTL United Kingdom
- Employees
- ZVRA N/A
- AUTL N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZVRA Health Care
- AUTL Health Care
- Exchange
- ZVRA Nasdaq
- AUTL Nasdaq
- Market Cap
- ZVRA 627.7M
- AUTL 625.4M
- IPO Year
- ZVRA 2015
- AUTL 2018
- Fundamental
- Price
- ZVRA $9.02
- AUTL $1.50
- Analyst Decision
- ZVRA Strong Buy
- AUTL Strong Buy
- Analyst Count
- ZVRA 10
- AUTL 5
- Target Price
- ZVRA $22.67
- AUTL $9.12
- AVG Volume (30 Days)
- ZVRA 1.6M
- AUTL 2.8M
- Earning Date
- ZVRA 08-12-2025
- AUTL 08-12-2025
- Dividend Yield
- ZVRA N/A
- AUTL N/A
- EPS Growth
- ZVRA N/A
- AUTL N/A
- EPS
- ZVRA N/A
- AUTL N/A
- Revenue
- ZVRA $62,020,000.00
- AUTL $29,934,000.00
- Revenue This Year
- ZVRA $329.57
- AUTL $634.25
- Revenue Next Year
- ZVRA $55.29
- AUTL $93.16
- P/E Ratio
- ZVRA N/A
- AUTL N/A
- Revenue Growth
- ZVRA 161.81
- AUTL 185.17
- 52 Week Low
- ZVRA $6.19
- AUTL $1.11
- 52 Week High
- ZVRA $13.16
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- ZVRA 38.21
- AUTL 25.52
- Support Level
- ZVRA $9.16
- AUTL $1.53
- Resistance Level
- ZVRA $9.48
- AUTL $1.64
- Average True Range (ATR)
- ZVRA 0.57
- AUTL 0.15
- MACD
- ZVRA -0.09
- AUTL -0.04
- Stochastic Oscillator
- ZVRA 18.99
- AUTL 1.48
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.